As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion. Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.

Mr. Norrett brings over two decades of experience across commercial strategy, business operations and corporate development for both established and emerging biotechnology companies. Most recently, he served as Chief Business Officer of Sierra Oncology.  There, he led commercial operations and corporate development and communications and completed the $1.9 billion acquisition by GSK.  Prior to Sierra Oncology, Mr. Norrett was Chief Commercial Officer at Angion Biomedica, setting commercial strategy and positioning for its pipeline and its successful IPO.  Previously, he served as Vice President of Marketing, Market Access and Commercial Operations at Aimmune Therapeutics, acquired by Nestle Health Science, where he built commercial operations for the launch of Palforzia®, the first approved therapy for pediatric peanut allergy. Prior to joining Aimmune, Mr. Norrett was Vice President, Market Access and Commercial Development at ZS Pharma, acquired by AstraZeneca for $2.7 billion. Mr. Norrett also held increasingly senior commercial leadership roles at Exelixis and Genentech, where he launched multiple products across oncology and rare disease.  Kevin also served as an Associate in SG Cowen’s Health Care Investment Banking Group, closing over 20 transactions worth over $2 billion. Mr. Norrett earned an MBA from the Haas School of Business at the University of California, Berkeley, an MS in Biochemistry and Molecular Biology from University of California, Los Angeles and a BS in Biological Sciences from the University of California, Davis.

Georgia Erbez is a seasoned financial and operations executive, most recently serving as Chief Operating Officer at Walking Fish Therapeutics, a private B cell therapy company. Prior to that, she served as the Chief Financial Officer of Harpoon Therapeutics, a public T cell therapy company. Ms. Erbez also held the role of Chief Business Officer and Chief Financial Officer at Zosano Pharma Corp., and has served as Chief Financial Officer for Revolution Medicines, Asterias Biotherapeutics and Raptor Pharmaceuticals. Earlier in her career, Ms. Erbez held senior positions in investment banking, most recently at Cowen and Company and Jefferies. In addition, she was a Managing Director at Axiom Financial Partners, a life-sciences consulting firm. She currently serves as a member of the board of directors of Coherus BioSciences. Ms. Erbez holds a bachelor’s degree in international relations with an emphasis on economics from the University of California, Davis.

Alison Moore brings to Codexis significant experience as a biotechnology and pharmaceutical executive, including an extensive background in biomanufacturing. She is former Chief Technical Officer of Allogene Therapeutics, a pioneering clinical-stage company advancing CAR-T therapies. Prior to Allogene she spent a total of 20 years at Amgen, most recently as Senior Vice President, Process Development, and including roles in Supply Chain and Manufacturing. Dr. Moore also has experience at Genentech as a Director in Chemistry, Manufacturing and Controls, and Regulatory Affairs. Dr. Moore holds a bachelor’s degree in Pharmacology with Honors and a PhD in Cell Biology from Manchester University, England.

Karen Frechou-Armijo is a forward-thinking human resources executive with more than two decades of experience driving transformative people strategies across life sciences and technology sectors. At Codexis, she leads all aspects of human capital strategy, including organizational design, talent acquisition and development, culture, and employee experience. Her leadership is instrumental in shaping Codexis’ high-performance, innovation-driven culture as the company scales and evolves in the synthetic biology space.

Prior to joining Codexis, Karen served as Vice President of Human Resources at Cepheid, where she guided the company through a period of hypergrowth, expanding the workforce more than sevenfold over five years. Known for her ability to align people strategy with business goals, Karen brings a track record of significant achievement and impact.